One of the newest active mass tort MDLs in the federal court system officially opened its doors in February 2026, and patients who received the Cartiva Synthetic Cartilage Implant for big-toe arthritis are now at a critical decision point. The Cartiva implant lawsuit landscape shifted dramatically when the Judicial Panel on Multidistrict Litigation consolidated all federal cases into a single coordinated proceeding — just months after a sweeping FDA recall confirmed what many injured patients had long suspected: this device was failing at rates no one warned them about.
What Is the Cartiva Synthetic Cartilage Implant?
The Cartiva Synthetic Cartilage Implant (SCI) is a small cylindrical device made from polyvinyl alcohol (PVA) hydrogel — sometimes called a cryogel — designed to treat hallux rigidus, a progressive arthritic condition affecting the first metatarsophalangeal joint at the base of the big toe. Rather than fusing the joint and permanently eliminating motion, the Cartiva SCI was marketed as a motion-preserving alternative: a way to relieve pain while keeping the joint functional.
For patients suffering from debilitating big-toe arthritis, that promise was compelling. Fusion surgery, while effective, permanently eliminates joint movement and comes with its own recovery challenges. The Cartiva implant offered what seemed like a better path forward — until, for thousands of patients, it didn’t. To understand how defective medical device claims are evaluated and what compensation may be available, patients can explore a medical malpractice calculator as a starting point for understanding the scope of their potential damages.
The FDA Recall That Changed Everything
In October 2024, the U.S. Food and Drug Administration issued a Class II recall for the Cartiva Synthetic Cartilage Implant, covering all lots distributed from July 2016 through October 2024. A Class II recall designation means the FDA has determined that use of the device may cause temporary or medically reversible adverse health consequences, though the probability of serious harm is considered lower than a Class I recall.
The language in the FDA recall record is striking in its specificity. According to the recall documentation, the FDA stated that implanted patients may experience a higher-than-expected occurrence of revision, removal, implant subsidence, displacement, pain, nerve damage, or fragmentation. That language — “higher-than-expected” — sits at the heart of every pending Cartiva implant lawsuit: patients allege they were never warned those risks existed at the rates the manufacturer knew or should have known about.
MDL 3172: Breaking Down the Federal Consolidation
On February 5, 2026, the Judicial Panel on Multidistrict Litigation formally centralized all federal Cartiva Synthetic Cartilage Implant cases into In re: Cartiva Synthetic Cartilage Implant Products Liability Litigation, MDL No. 3172, master docket 4:26-md-03172-KGB, in the U.S. District Court for the Eastern District of Arkansas. The case is assigned to Judge Kristine G. Baker.
The path to MDL formation moved quickly once it began. Seven federal cases were filed in October 2025, oral argument before the JPML took place on January 29, 2026, and the panel issued its transfer order just one week later. At opening, five actions were transferred directly into the MDL, with nine additional tag-along actions pending across seven federal districts. By March 2, 2026, the docket had grown to 14 pending lawsuits — a number that legal observers expect to grow substantially as more injured patients and their attorneys file claims. You can review the JPML’s official docket records for current case counts and transfer orders.
Why the Eastern District of Arkansas?
The JPML’s venue selection was deliberate. The Panel assigned the litigation to the Eastern District of Arkansas based in part on the proximity of relevant evidence and witnesses to Memphis, Tennessee — where Wright Medical Group, one of the key defendants, was headquartered before its acquisition by Stryker Corporation in 2020.
The JPML Rejected Defendants’ Consolidation Objections
Notably, the JPML did not grant defendants’ request to sidestep formal MDL consolidation. Cartiva and the other defendants argued that quiet settlement negotiations and tolling agreements were already resolving claims on an individual basis, making formal centralization unnecessary. The Panel disagreed, finding that these cases share core factual questions about device testing, product labeling, representations made to the FDA, and the recall itself — exactly the kind of common issues that MDL consolidation is designed to resolve efficiently.
Who Are the Defendants in the Cartiva Implant Lawsuit?
The corporate chain of responsibility in the Cartiva implant lawsuit runs through three entities. Cartiva, Inc. was the original manufacturer and developer of the device. Wright Medical Group acquired Cartiva and became the corporate successor responsible for the product. Then, in 2020, Stryker Corporation — one of the world’s largest medical device companies — acquired Wright Medical Group, making Stryker the current corporate successor now facing coordinated federal pretrial proceedings.
That acquisition history matters legally because it affects which corporate entity bears liability for which time periods — questions that pretrial proceedings in MDL 3172 will need to resolve. Understanding corporate successor liability in the context of defective medical devices is an area where Cornell Law School’s Legal Information Institute provides accessible background on products liability doctrine.
Core Allegations and Patient Injuries
What Plaintiffs Are Alleging
The allegations in the Cartiva implant lawsuit cluster around four central claims: defective design, failure to adequately research long-term device performance, underreporting of failure rates to federal regulators, and failure to warn physicians and patients of known risks. Specifically, plaintiffs allege that defendants knew or should have known about risks including implant loosening, shrinkage, bone erosion, loss of motion, and subsidence — and that this information was not adequately disclosed.
Injuries Reported by Claimants
The injuries described in filed and anticipated claims paint a consistent picture of device failure. Patients report persistent and worsening pain after implantation, implant subsidence (sinking into the bone), implant displacement, nerve damage, bone erosion around the implant site, and device fragmentation. Many patients ultimately required revision surgery — and in a deeply ironic outcome, a significant number of revision surgeries resulted in permanent toe fusion, the very procedure the Cartiva SCI was marketed as an alternative to. Those who have suffered through multiple surgeries and permanent disability may want to explore a personal injury settlement calculator to get a general sense of how various injury factors affect case value.
Key Facts and Timeline: Cartiva MDL 3172 at a Glance
| Event / Data Point | Detail | Source / Reference |
|---|---|---|
| FDA Class II Recall Issued | October 2024; all lots distributed July 2016 – October 2024 | FDA.gov |
| First Federal Cases Filed | October 2025 (7 cases triggering MDL petition) | JPML Transfer Order, MDL 3172 |
| JPML Oral Argument | January 29, 2026 | JPML Hearing Session |
| MDL Consolidation Order | February 5, 2026 | JPML.uscourts.gov |
| Assigned Court | U.S. District Court, Eastern District of Arkansas | MDL No. 3172 |
| Presiding Judge | Judge Kristine G. Baker | 4:26-md-03172-KGB |
| Cases at MDL Opening | 5 direct transfers + 9 tag-along actions pending | JPML Transfer Order |
| Cases as of March 2, 2026 | 14 pending federal lawsuits | MDL Docket, E.D. Ark. |
| Bellwether Trial Date | Not yet set | MDL Pretrial Proceedings |
| Global Settlement Announced | None as of June 2026 | Active MDL Status |
Where the Litigation Stands Now and What Comes Next
MDL 3172 is at the earliest stages of what will likely be years of coordinated federal litigation. No bellwether trial date has been set, and no global settlement has been announced. The MDL process typically unfolds in phases: initial case management orders, the formation of a Plaintiffs’ Steering Committee, extensive document discovery, expert witness proceedings, and then the selection of bellwether cases — representative trials designed to test the strength of core allegations and inform settlement negotiations.
The current case count of 14 federal lawsuits is widely expected to grow as awareness of the Cartiva implant lawsuit increases and as attorneys identify additional patients who experienced device failure. Patients who had the Cartiva SCI implanted between July 2016 and October 2024 and who subsequently required revision surgery or experienced significant complications are the core potential claimant pool. The Administrative Office of U.S. Courts publishes annual data on MDL proceedings that provides useful context for understanding how these complex cases move through the federal system.
For patients wondering whether their experience qualifies as part of this litigation, the critical factors are: receiving the Cartiva SCI within the recall period, experiencing complications consistent with those described in the FDA recall (subsidence, displacement, pain, nerve damage, fragmentation), and having undergone revision surgery or conversion to toe fusion as a result. Statutes of limitations vary by state, making the timing of any legal consultation genuinely important — not as a scare tactic, but as a practical reality of how personal injury law works.
Frequently Asked Questions About the Cartiva Implant Lawsuit
Who qualifies to file a Cartiva implant lawsuit in 2026?
Patients who received the Cartiva Synthetic Cartilage Implant between July 2016 and October 2024 — the period covered by the FDA’s Class II recall — and who subsequently experienced complications such as implant subsidence, displacement, fragmentation, nerve damage, bone erosion, or required revision surgery or permanent toe fusion may qualify to file a Cartiva implant lawsuit. The FDA’s own recall language references a “higher-than-expected” rate of these complications, which supports the core failure-to-warn and defective design allegations that underpin active claims in MDL 3172.
What is MDL 3172 and how does it affect individual cases?
MDL No. 3172, formally titled In re: Cartiva Synthetic Cartilage Implant Products Liability Litigation, is a federal multidistrict litigation proceeding that centralizes all federal Cartiva cases before Judge Kristine G. Baker in the Eastern District of Arkansas. Consolidation does not eliminate individual cases — each plaintiff retains their own lawsuit. Instead, MDL consolidation coordinates pretrial proceedings like discovery and expert testimony to eliminate duplication and inconsistent rulings. If the MDL does not resolve through a global settlement, individual cases can be remanded to their home districts for trial.
What are the main allegations against Stryker and Wright Medical in the Cartiva lawsuit?
Plaintiffs in the Cartiva implant lawsuit allege four primary theories of liability: (1) defective design — that the PVA hydrogel implant was not adequately engineered for long-term load-bearing function in the metatarsophalangeal joint; (2) failure to research — that defendants did not conduct adequate long-term studies on device performance before and after market; (3) failure to report — that known failure rates were underreported to the FDA; and (4) failure to warn — that physicians and patients were not given adequate information about risks including subsidence, bone erosion, loosening, and the likelihood of requiring revision surgery or permanent fusion.
How long will the Cartiva MDL litigation take, and when might there be a settlement?
As of June 2026, MDL 3172 is approximately four months old, no bellwether trial date has been set, and no global settlement has been announced. For context, major medical device MDLs often take several years from formation to resolution. The typical path involves early case management orders, discovery from defendants, expert witness proceedings, and bellwether trials — which are representative cases tried to help both sides evaluate overall case values and settlement ranges. A global settlement could potentially be negotiated at any point in this process, but the current stage of the litigation makes a near-term resolution unlikely. Patients filing claims now would be entering at the ground floor of an actively developing MDL.
Does it matter which state you live in for a Cartiva implant lawsuit?
Because the Cartiva implant lawsuit is centralized as a federal MDL, cases from all states are coordinated in the Eastern District of Arkansas for pretrial purposes, regardless of where the plaintiff lives or where the surgery occurred. However, state law still matters significantly: the substantive legal standards for products liability, the applicable statute of limitations (which varies by state), and damages calculations can all differ based on which state’s law governs a particular plaintiff’s case. This is one reason why understanding your individual state’s filing deadlines is important — waiting too long to investigate a potential claim could affect your ability to participate in the litigation even as the MDL grows.
This content is provided for informational purposes only and does not constitute legal advice or create an attorney-client relationship.
Related reading: personal injury settlement calculator
Related reading: medical malpractice calculator
Victoria Chambers is a mass tort and class action research analyst with extensive knowledge of multi-district litigation (MDL), defective product cases, dangerous drug lawsuits, and toxic exposure claims across the United States. Victoria is not an attorney and the information provided is for educational purposes only.